# UVA Health: CASS4 gene controls microglia that compact amyloid plaques in a mouse Alzheimer's model

- Published: 2026-11-11 03:10 UTC
- Section: Life & Health › Neurotechnology
- Tags: CASS4 gene, Alzheimer's risk gene, microglia, amyloid-beta plaques, Alzheimer's biomarker, neurodegenerative diseases, UVA Health, Journal of Experimental Medicine, John Lukens
- URL: https://realtech.media/news/rt-1c96bb6486c3e4f0f1c27a61_uva_health_cass4/

**In mice, loss of CASS4 left microglia unable to contain amyloid-beta plaques, which grew and spread faster. The authors propose the gene as a biomarker and a therapeutic target.**

![UVA Health: CASS4 gene controls microglia that compact amyloid plaques in a mouse Alzheimer's model](https://realtech.media/media/2026/11/bec629a0ab948479.jpg)
*Syed07, Wikimedia Commons, CC BY 4.0*

Researchers at UVA Health, led by John Lukens, PhD, studied the CASS4 gene, which numerous studies had identified as a risk factor for Alzheimer's disease. In experiments on lab mice, they found that the gene helps direct microglia, the brain's immune cells that clear waste, according to news-medical.net [1]. The results were published in the Journal of Experimental Medicine.

Alzheimer's disease affects more than 6 million Americans and is the sixth-leading cause of death in the United States. Its development is accompanied by the buildup of amyloid-beta plaques and tau tangles in the brain. Recent research indicates that the immune system, and microglia in particular, may play a central role.

## What CASS4 does in microglia

When microglia work properly, they form protective barriers around amyloid-beta plaques and compact them as tightly as possible to limit the damage. When the proper function of CASS4 was disrupted in mice, the microglia responded poorly to the forming plaques and were far less able to contain and compact the toxic proteins [1]. The plaques grew more quickly and spread more aggressively. The mice also showed damage to neurons and cognitive decline.

The loss of CASS4 triggered a cascade of changes in gene activity. According to the researchers, these changes may contribute not only to Alzheimer's but also to other neurodegenerative diseases.

First author Addie Walsh, a physiology graduate student at UVA, said that almost nothing was known about what the gene does or how it affects the brain during disease. Many in the field had presumed that CASS4 acts in neurons. Lukens said the new data show that it predominantly acts through the immune system.

## Biomarker and therapy hypotheses

The authors suggest that defective CASS4 activity may serve as an early biomarker for detecting Alzheimer's. They also propose that strategies boosting its function may offer a treatment approach. These are hypotheses: the work was done in mice, and no treatment has been tested.

According to Lukens, the team is now examining the role of CASS4 in other neurodegenerative disorders and developing strategies to target it therapeutically. The paper is titled "Alzheimer's genetic risk factor CASS4 controls microglial focal adhesion biology and amyloidosis" (DOI: 10.1084/jem.20260104) [1].

## Sources

1. [news-medical.net](https://www.news-medical.net/news/20261110/Targeting-brain-cleaning-gene-could-help-treat-or-prevent-Alzheimers.aspx)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-1c96bb6486c3e4f0f1c27a61_uva_health_cass4/